

SCHEDULE 2 - TEMPLATE

| | Full Name (Art. 1.01) | HCPs: City of Principal Practice | Country of Principal Practice | Principal Practice Address | Unique Country Identifier | Donations and Grants to HCOs | Contribution to Costs of Events | | | Fee for Service and Consultancy | | Total | |
|--|---|--|-------------------------------|--|---------------------------|--|---------------------------------|------|------|---------------------------------|------|-------|-------|
| | | HCOs: City Where Registered (Art. 3) | (Schedule 1) | (Art. 3) | (Art. 3) | (Art. 3.01.1.a) | (Art. 3.01.1.b & 3.01.2.a) | | | (Art. 3.01.1.c & 3.01.2.c) | | | |
| | | Sponsorship Agreements with HCOs/ Third Parties Appointed by HCOs to Manage an Event | Registration Fees | Travel & Accommodation | Fees | Related Expenses Agreed in the Fee for Service or Consultancy Contract, Including Travel & Accommodation Relevant to the Contract | | | | | | | |
| INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual recipient or public authorities' consultation only, as appropriate) | | | | | | | | | | | | | |
| | Intensive Care Nurse Mathilde Christensen | Stavanger | Norway | Gerd-Ragna Bloch Thoresen Gate 8, 4011 | | N/A | N/A | 0 | 0 | 3000 | 0 | 3000 | |
| | Klinisk ernæringsfysiolog Camilla Hennig | Kristiansand | Norway | Egsvæien 100, 4615 | | N/A | N/A | 0 | 0 | 6000 | 0 | 6000 | |
| | Overlege Kristin Kaasen Jørgensen | Lørenskog | Norway | Sykehusveien 25, 1478 | 270567 | N/A | N/A | 0 | 0 | 7000 | 0 | 7000 | |
| | Intensive Care Nursen Maria Klette | Stavanger | Norway | Gerd-Ragna Bloch Thoresen Gate 8, 4011 | | N/A | N/A | 0 | 0 | 3000 | 0 | 3000 | |
| | Overlege Angélique Tiarks | Levanger | Norway | Kirkegata 2, 7602 | N/A | N/A | N/A | 0 | 0 | 6000 | 0 | 6000 | |
| OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons | | | | | | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients (Art. 3.02) | | | | | N/A | N/A | 0 | 0 | 0 | 0 | 0 | |
| | Number of Recipients in Aggregate Disclosure (Art. 3.02) | | | | | N/A | N/A | 0 | 0 | 0 | 0 | 0 | |
| | % of the number of Recipients included in the Aggregate Disclosure in the total Number of Recipients Disclosed (Art. 3.02) | | | | | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% | N/A | |
| HCPs | | | | | | | | | | | | | |
| INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual recipient or public authorities' consultation only, as appropriate) | | | | | | | | | | | | | |
| OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons | | | | | | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients (Art. 3.02) | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | Number of Recipients in aggregate disclosure (Art. 3.02) | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed (Art. 3.02) | | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A | |
| HCOs | | | | | | | | | | | | | |
| AGGREGATE DISCLOSURE | | | | | | | | | | | | | |
| Research & Development | Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1 | | | | | | | | | | | 0 | 25000 |